SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Maicol Mancini, Yosef Yarden, Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors, Seminars in Cell & Developmental Biology, 2016, 50, 164

    CrossRef

  2. 2
    Tetsuo Mashima, Masaru Ushijima, Masaaki Matsuura, Satomi Tsukahara, Kazuhiro Kunimasa, Aki Furuno, Sakae Saito, Masami Kitamura, Taeko Soma-Nagae, Hiroyuki Seimiya, Shingo Dan, Takao Yamori, Akihiro Tomida, Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation, Cancer Science, 2015, 106, 7
  3. 3
    K. Sakai, S. Aoki, K. Matsumoto, Hepatocyte growth factor and Met in drug discovery, Journal of Biochemistry, 2015, 157, 5, 271

    CrossRef

  4. 4
    Christian Rolfo, Nele Van Der Steen, Patrick Pauwels, Federico Cappuzzo, Onartuzumab in lung cancer: the fall of Icarus?, Expert Review of Anticancer Therapy, 2015, 15, 5, 487

    CrossRef

  5. 5
    I. Eke, K. Zscheppang, E. Dickreuter, L. Hickmann, E. Mazzeo, K. Unger, M. Krause, N. Cordes, Simultaneous  1 integrin-EGFR Targeting and Radiosensitization of Human Head and Neck Cancer, JNCI Journal of the National Cancer Institute, 2015, 107, 2, dju419

    CrossRef

  6. 6
    Ian Pike, Emma Lahert, A Global Phosphorylation Assay, Clinical OMICs, 2014, 1, 3, 26

    CrossRef

  7. 7
    Fariz Nurwidya, Fumiyuki Takahashi, Akiko Murakami, Isao Kobayashi, Motoyasu Kato, Takehito Shukuya, Ken Tajima, Naoko Shimada, Kazuhisa Takahashi, Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors, Respiratory Investigation, 2014, 52, 2, 82

    CrossRef

  8. 8
    D. Ross Camidge, William Pao, Lecia V. Sequist, Acquired resistance to TKIs in solid tumours: learning from lung cancer, Nature Reviews Clinical Oncology, 2014, 11, 8, 473

    CrossRef

  9. 9
    Junya Nakade, Shinji Takeuchi, Takayuki Nakagawa, Daisuke Ishikawa, Takako Sano, Shigeki Nanjo, Tadaaki Yamada, Hiromichi Ebi, Lu Zhao, Kazuo Yasumoto, Kunio Matsumoto, Kazuhiko Yonekura, Seiji Yano, Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation, Journal of Thoracic Oncology, 2014, 9, 6, 775

    CrossRef

  10. 10
    Sei-Hoon Yang, Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors, Tuberculosis and Respiratory Diseases, 2013, 75, 5, 188

    CrossRef

  11. 11
    Takashi Ninomiya, Nagio Takigawa, Shinichi Toyooka, Katsuyuki Hotta, Mitsune Tanimoto, Katsuyuki Kiura, New treatment strategy for patients withEGFR-mutant lung cancer, Lung Cancer Management, 2013, 2, 6, 505

    CrossRef

  12. 12
    Helmut H. Popper, Ulrike Gruber-Moesenbacher, Leonhard Müllauer, Georg Hutarew, Michael Vesely, Robert Pirker, Wolfgang Hilbe, Ferdinand Ploner, Ulrike Setinek, Wolfgang Hulla, Hans Maier, William Sterlacci, Klaus Kirchbacher, Rainer Kolb, Maximilian Hochmair, Gerald Webersinke, Elvira Stacher, Patricia Grabher, Tamara Hernler, Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer, memo - Magazine of European Medical Oncology, 2013, 6, 2, 83

    CrossRef

  13. 13
    Martin Reck, Niels Reinmuth, David F Heigener, First- and second-line treatment of non-small-cell lung cancer patients withEGFRmutation-positive tumors, Lung Cancer Management, 2012, 1, 3, 201

    CrossRef